CDIOHealthcare · BiotechnologyCDIO Stock Forecast: Cardio Diagnostics Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.
CDIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Cardio Diagnostics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Cardio Diagnostics Holdings, Inc. — and when they’d sell — is the membership.
CDIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CDIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2024 | Benchmark | Reiterates | Speculative Buy | $2.00 |
| 6 June 2024 | Benchmark | Maintains | Speculative Buy | — |
| 19 Apr 2024 | Benchmark | Maintains | Speculative Buy | — |
| 15 June 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 22 May 2023 | Northland Capital Markets | Initiates | Outperform | — |
| 18 Apr 2023 | Benchmark | Reiterates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CDIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Cardio Diagnostics Holdings, Inc. (CDIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.4×
- Price / sales
- 278.7×
- Price / book
- 0.5×
- EV / EBITDA
- 0.3×
Cheaper than 79% of US stocks
Cheaper than 2% of US stocks
Cheaper than 84% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- 185.1%
- Earnings growth (YoY)
- 185.1%
- Gross margin
- —
- Operating margin
- −66598.4%
- Net margin
- 0.0%
Higher than 96% of US stocks
Higher than 91% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −65.6%
- Return on assets
- −38.0%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CDIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDIO appears on the weeks it earns a place.
Frequently asked questions about CDIO stock
Is CDIO stock a buy right now?
Of the 1 analysts covering Cardio Diagnostics Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardio Diagnostics Holdings, Inc. 24 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CDIO?
As at 1 Aug 2026, Cardio Diagnostics Holdings, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the CDIO stock forecast for 2030?
No analyst covering Cardio Diagnostics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDIO are extrapolating price history, which says nothing about the business.
How has CDIO stock performed over the past year?
Cardio Diagnostics Holdings, Inc. returned -57.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cardio Diagnostics Holdings, Inc. do?
Cardio Diagnostics Holdings Inc. is a biotechnology company in the healthcare sector that develops and commercializes epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management.
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings Inc. is a biotechnology company in the healthcare sector that develops and commercializes epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management. Its primary offerings include Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment blood test targeting events like heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease; and Actionable Clinical Intelligence, a platform delivering epigenetic and genetic insights to clinicians for improved chronic care management. The company also provides CardioInnovate360, a research-use-only solution supporting biopharmaceutical discovery and validation for cardiovascular diseases, and HeartRisk, a SaaS platform offering real-time cardiovascular risk intelligence from aggregated clinical data. Cardio Diagnostics Holdings Inc. serves telemedicine providers, concierge practices, longevity clinics, risk-bearing provider organizations, employer organizations, and correctional facilities, leveraging AI-driven multi-omics technology for personalized molecular insights beyond traditional risk factors. Founded in 2017 and headquartered in Chicago, Illinois, it focuses on making cardiovascular care more accessible and precise.
CEO Dr. Meeshanthini V. Dogan Ph.D. · 15 employees · United States · https://cdio.ai